Cargando…

Surgiflo® hemostatic matrix versus NasoPore® nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: A randomized controlled trial

BACKGROUND: To help ensure adequate hemostasis immediately following potassium titanyl phosphate (KTP) laser treatment, many centres treating hereditary hemorrhagic telangiectasia (HHT) routinely use nasal packing post‐operatively. The purpose of this study was to compare hemostatic thrombin matrix...

Descripción completa

Detalles Bibliográficos
Autores principales: Pyne, Justin M., Murray, Scott, Kelly, Brendan C., Song, Jin Soo, Rosvall, Brandon R., Côté, David W. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171071/
https://www.ncbi.nlm.nih.gov/pubmed/37181404
http://dx.doi.org/10.1002/lio2.1023
_version_ 1785039353950502912
author Pyne, Justin M.
Murray, Scott
Kelly, Brendan C.
Song, Jin Soo
Rosvall, Brandon R.
Côté, David W. J.
author_facet Pyne, Justin M.
Murray, Scott
Kelly, Brendan C.
Song, Jin Soo
Rosvall, Brandon R.
Côté, David W. J.
author_sort Pyne, Justin M.
collection PubMed
description BACKGROUND: To help ensure adequate hemostasis immediately following potassium titanyl phosphate (KTP) laser treatment, many centres treating hereditary hemorrhagic telangiectasia (HHT) routinely use nasal packing post‐operatively. The purpose of this study was to compare hemostatic thrombin matrix with standard packing for postoperative bleeding, patient pain, and comfort. METHODS: A prospective, randomized, double‐blinded, non‐inferiority study was conducted with participants at an HHT centre of excellence (COE) and randomized to the treatment group with reconstituted thrombin gelatin matrix (Surgiflo®) or control group with a biodegradable synthetic polyurethane foam (NasoPore®). Adult subjects with confirmed HHT and moderate to severe epistaxis (a minimum calculated epistaxis severity score [ESS] of 4.0) warranting KTP laser treatment were recruited. Data was collected 2 weeks post operatively by a blinded reviewer completing a visual outcomes evaluation and each patient completing a subjective symptoms questionnaire. Non‐parametric statistical analysis was employed. RESULTS: Twenty‐eight adult patients were randomized to the treatment and control arms with comparable preoperative epistaxis severity scores. Postoperative nasal bleeding was equivalent. Significantly less pain was found in the treatment arm (p = .005). While there were trends towards less obstruction and increased satisfaction in the treatment group as well as less crusting in the control group, these findings were not statistically significant. Allocation to the treatment group was associated with an approximately $75 higher cost. CONCLUSIONS: When compared to NasoPore® for hemostasis, Surgiflo® hemostatic matrix performed equivalently while causing less discomfort in HHT patients following nasal KTP treatment. LEVEL OF EVIDENCE: 1b.
format Online
Article
Text
id pubmed-10171071
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-101710712023-05-11 Surgiflo® hemostatic matrix versus NasoPore® nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: A randomized controlled trial Pyne, Justin M. Murray, Scott Kelly, Brendan C. Song, Jin Soo Rosvall, Brandon R. Côté, David W. J. Laryngoscope Investig Otolaryngol Allergy, Rhinology, and Immunology BACKGROUND: To help ensure adequate hemostasis immediately following potassium titanyl phosphate (KTP) laser treatment, many centres treating hereditary hemorrhagic telangiectasia (HHT) routinely use nasal packing post‐operatively. The purpose of this study was to compare hemostatic thrombin matrix with standard packing for postoperative bleeding, patient pain, and comfort. METHODS: A prospective, randomized, double‐blinded, non‐inferiority study was conducted with participants at an HHT centre of excellence (COE) and randomized to the treatment group with reconstituted thrombin gelatin matrix (Surgiflo®) or control group with a biodegradable synthetic polyurethane foam (NasoPore®). Adult subjects with confirmed HHT and moderate to severe epistaxis (a minimum calculated epistaxis severity score [ESS] of 4.0) warranting KTP laser treatment were recruited. Data was collected 2 weeks post operatively by a blinded reviewer completing a visual outcomes evaluation and each patient completing a subjective symptoms questionnaire. Non‐parametric statistical analysis was employed. RESULTS: Twenty‐eight adult patients were randomized to the treatment and control arms with comparable preoperative epistaxis severity scores. Postoperative nasal bleeding was equivalent. Significantly less pain was found in the treatment arm (p = .005). While there were trends towards less obstruction and increased satisfaction in the treatment group as well as less crusting in the control group, these findings were not statistically significant. Allocation to the treatment group was associated with an approximately $75 higher cost. CONCLUSIONS: When compared to NasoPore® for hemostasis, Surgiflo® hemostatic matrix performed equivalently while causing less discomfort in HHT patients following nasal KTP treatment. LEVEL OF EVIDENCE: 1b. John Wiley & Sons, Inc. 2023-03-21 /pmc/articles/PMC10171071/ /pubmed/37181404 http://dx.doi.org/10.1002/lio2.1023 Text en © 2023 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Allergy, Rhinology, and Immunology
Pyne, Justin M.
Murray, Scott
Kelly, Brendan C.
Song, Jin Soo
Rosvall, Brandon R.
Côté, David W. J.
Surgiflo® hemostatic matrix versus NasoPore® nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: A randomized controlled trial
title Surgiflo® hemostatic matrix versus NasoPore® nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: A randomized controlled trial
title_full Surgiflo® hemostatic matrix versus NasoPore® nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: A randomized controlled trial
title_fullStr Surgiflo® hemostatic matrix versus NasoPore® nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: A randomized controlled trial
title_full_unstemmed Surgiflo® hemostatic matrix versus NasoPore® nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: A randomized controlled trial
title_short Surgiflo® hemostatic matrix versus NasoPore® nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: A randomized controlled trial
title_sort surgiflo® hemostatic matrix versus nasopore® nasal packing following postassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: a randomized controlled trial
topic Allergy, Rhinology, and Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171071/
https://www.ncbi.nlm.nih.gov/pubmed/37181404
http://dx.doi.org/10.1002/lio2.1023
work_keys_str_mv AT pynejustinm surgiflohemostaticmatrixversusnasoporenasalpackingfollowingpostassiumtitanylphosphatelasersurgeryforhereditaryhemorrhagictelangiectasiaarandomizedcontrolledtrial
AT murrayscott surgiflohemostaticmatrixversusnasoporenasalpackingfollowingpostassiumtitanylphosphatelasersurgeryforhereditaryhemorrhagictelangiectasiaarandomizedcontrolledtrial
AT kellybrendanc surgiflohemostaticmatrixversusnasoporenasalpackingfollowingpostassiumtitanylphosphatelasersurgeryforhereditaryhemorrhagictelangiectasiaarandomizedcontrolledtrial
AT songjinsoo surgiflohemostaticmatrixversusnasoporenasalpackingfollowingpostassiumtitanylphosphatelasersurgeryforhereditaryhemorrhagictelangiectasiaarandomizedcontrolledtrial
AT rosvallbrandonr surgiflohemostaticmatrixversusnasoporenasalpackingfollowingpostassiumtitanylphosphatelasersurgeryforhereditaryhemorrhagictelangiectasiaarandomizedcontrolledtrial
AT cotedavidwj surgiflohemostaticmatrixversusnasoporenasalpackingfollowingpostassiumtitanylphosphatelasersurgeryforhereditaryhemorrhagictelangiectasiaarandomizedcontrolledtrial